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Anti-retroviral therapy in the treatment of HIV (human 
immunodeficiency virus) aims to lower the viral load and improve 
immune function. Numerous interventions in the management of 
HIV seropositive patients are aimed to maximise individual patient 
adherence to treatment.
Introduction 
The HIV pandemic has far exceeded 
projections over the past decade. At the end 
of 2008 there were:
•	 an	estimated	33.4	million	people	living	
with HIV worldwide,
•	 an	estimated	2.7	million	new	HIV	
infections, and 
•	 an	estimated	2.0	million	AIDS	(acquired	
immunodeficiency syndrome)-related 
deaths.1
With regards to the local scenario, 
there were 30 new HIV infections and one 
AIDS-related death in Malta, in 2008.2 In 
Malta, HIV testing is totally confidential, 
and is available free of charge to anyone.3 
All patients are given a unique code number 
and only this number appears on all request 
forms. This procedure is used to eliminate 
the true identity of patients throughout the 
process – thus protecting confidentiality.
Aetiology and pathology of HIV
HIV is a retrovirus that infects cells of 
the immune system, leading to a specific 
decline in the CD4+ helper T cells. Immune 
responses to certain antigens begin to 
decline, and the host fails to adequately 
respond to opportunistic infections and 
normally harmless commensal organisms. 
The widespread use of anti-retroviral 
therapy has had the most profound influence 
on reducing opportunistic infection-related 
mortality in HIV-infected persons. However, 
opportunistic infections remain a leading 
cause of morbidity and mortality in HIV-
infected persons.
Anti-retroviral therapy
The goal of anti-retroviral therapy in 
HIV infection is to increase the length 
and quality of life by improving immune 
function. This is achieved by reducing the 
amount of replicating virus to as low a level 
as possible, for a long as possible, in all 
sites where HIV-infected cells are present, 
thereby preventing infection of new cells and 
further damage to the immune system. The 
amount of replicating virus in the plasma can 
be assayed by measuring the concentration 
of HIV RNA, referred to as the viral load. In 
practical terms, the aim of anti-retroviral 
therapy is to lower the viral load to a value 
below the level of detection of the assay 
used. Achieving this with the currently 
available anti-retroviral agents involves 
appropriate selection of combination 
regimens to obtain an antiviral response, and 
excellent adherence to the regimen by the 
patient. In addition, consideration of a plan 
for salvage or second line regimen is required 
if initial therapy fails.
There are eleven anti-retroviral agents 
currently being used in Malta (Table 1). 
These can be divided into three classes:
1. Nucleoside reverse transcriptase inhibitors 
(NRTIs) 
 These were the first drugs to be licensed 
for the treatment of HIV infection. 
They are generally considered to be the 
backbone of anti-retroviral therapy when 
combined with protease inhibitors (PIs) 
or non-nucleoside reverse transcriptase 
inhibitors (NNRTIs).
2. Protease inhibitors (PIs)
 A dramatic decline in the clinical 
progression of HIV disease and HIV-
related deaths followed the introduction 
of PIs. The main drawbacks to PIs are 
the number of dose units that patients 
have to take, and the need for food 
restrictions.
3. Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs)
 These are the third class of drugs 
currently available to treat HIV infection. 
They are generally considered simpler to 
take than PIs, but are hampered by the 
fact that resistance develops quickly, and 
patients are usually resistance to all drugs 
within the class. 
These drugs act at different stages in the 
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Table 1. Anti-retroviral agents used locally
NRTIs Didanosine
 Lamivudine
 Stavudine
 Tenofovir
 Zidovudine
 
PIs Indinavir
 Lopinavir/ritonavir
 Ritonavir
 Saquinavir
 
NNRTIs Efavirenz
 Nevirapine
Table 2. Some common side effects of anti-retroviral drugs
Drug Side effect Management of side effect
  
Zidovudine Anaemia Change to another NRTI with less incidence of this adverse event (e.g.) tenofovir
  
  
Indinavir Crystalluria Change to another PI with less incidence of this adverse event (e.g.) 
 Hypercolesterolaemia lopinavir/ritonavir
   
  
Efavirenz Rash Change to another agent from the same class or a different class (e.g.) 
 Psychiatric symptoms nevirapine or lopinavir/ritonavir
HIV replication cycle. The first anti-retroviral 
agent to become commercially available was 
zidovudine in 1987, followed by didanosine 
and zalcitabine in 1993 – all of which are 
NRTIs. Initially, these drugs were used 
alone as mono-therapy (often sequentially, 
as each agent became available). It is now 
realized that rapid resistance develops to 
anti-retroviral drugs if they are not used in 
combination. Effective combination therapy 
consisting of three or more anti-retroviral 
drugs, or highly active anti-retroviral therapy 
(HAART), is now the accepted standard of 
care for HIV-infected individuals requiring 
treatment.
Initiation of treatment
The CD4+ T-cell count (or CD4 count) 
serves as the major clinical indicator of 
immune function in patients who have HIV 
infection. It is one of the key factors in 
deciding whether to initiate antiretroviral 
therapy and chemoprophylaxis for 
opportunistic infections, and is the strongest 
predictor of subsequent disease progression 
and survival.
Most major guidelines (British, European 
and American guidelines) agree that 
antiretroviral therapy should be initiated in 
all patients with a CD4 count <350 cells/
mm3. 4, 5, 6
Importance of strict adherence to 
treatment
HIV treatment is a chronic treatment and 
an expensive one too. Furthermore, strict 
adherence to an already complicated regimen 
is vital. Numerous international studies have 
concluded that less than 95% adherence is 
equivalent to treatment failure. Since most 
anti-retroviral drugs currently available 
exhibit cross resistance, development of 
resistance to a drug often means resistance 
to the entire class of drugs, thus limiting 
future treatment options. 
It is fair to say that HIV infection is 
no longer considered the terminal illness 
that it was 5 to 10 years ago, but it is now 
regarded as more of a chronic infection, 
manageable with antiviral therapy. However, 
current knowledge indicates that the therapy 
should be for life, a situation that makes the 
issue of adherence a real obstacle for some 
patients.
A thorough understanding of HIV 
therapy, including the importance of 
good adherence and the dangers of poor 
adherence, is an important basic tool to 
increasing adherence. The importance of 
adherence is always stressed to all patients, 
including all new patients prior to initiating 
therapy.
Learning the patient’s daily routine and 
incorporating dosing cues into that routine 
is a very helpful tool to increase adherence. 
Patients are actively encouraged to discuss 
any problems with fitting their daily doses 
with their daily activities.
Partial adherence is extremely common. 
When assessing adherence of patients 
already on treatment, a neutral approach 
to adherence history is preferred. Questions 
like: “How many doses have you missed or 
taken more than an hour late, in the past 
month?” are preferred to “Have you taken all 
medications as instructed?”
New patients are informed that this 
new medication schedule might seem a bit 
complex initially, but they would eventually 
learn to fit it into their daily routine — and 
it will feel less complex.
Two typical regimens that are currently 
being used in the treatment of HIV involve:
•	 Lopinavir/ritonavir	200/50mg	tablets,	
two tablets 12 hourly
•	 Zidovudine/lamivudine	300/150mg	
tablets, one tablet 12 hourly 
OR
•	 Efavirenz	600mg	tablets,	one	tablet	nocte
•	 Tenofovir	245mg	tablets,	one	tablet	daily
•	 Lamivudine	150mg	tablets	,	one	tablet	12	
hourly
Effects and side effects of medication
Anti-retrovirals are not a cure for HIV – 
however, they can help reduce the chances of 
getting opportunistic infections associated 
with HIV. This fact is clearly explained to all 
patients – it is considered to be of utmost 
importance that all patients are aware that 
HAART does not kill the virus, but suppresses 
it to a minimal level.
As a consequence, patients are made 
aware that they can still transmit the virus 
to others. All HIV-infected patients (even 
those with viral loads below detection limits) 
are counseled to avoid sexual and drug-use 
behaviors that may lead to transmission or 
acquisition of HIV or other pathogens.
The pharmacist goes over the important 
beneficial effects and side effects of every 
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Practice points
•	 The	goal	of	anti-retroviral	therapy	in	HIV	infection	is	to	increase	the	length	and	
quality of life by improving immune function.
•	 The	three	main	classes	of	anti-retrovirals	are	nucleoside	reverse	transcriptase	
inhibitors (NRTIs), protease inhibitors (PIs) and non-nucleoside reverse transcriptase 
inhibitors (NNRTIs).
•	 HIV	is	a	chronic	infection,	treatment	of	which	necessitates	very	strict	adherence	
(>95%).
•	 The	pharmacist	plays	a	major	in	offering	support	to	ensure	maximal	adherence.
•	 Pharmacists	must	always	be	on	the	look	out	for	any	potential	adverse	events	and	drug	
interactions when anti-retrovirals are taken in conjunction with other mediations.
medication the patient is taking. Potential 
common and severe adverse effects that may 
occur, and actions to prevent or minimize 
their occurrence, are always discussed.
For example, a patient initiating therapy 
with zidovudine is extensively counseled 
on the gastrointestinal adverse effects that 
are likely to occur, especially during the 
first weeks of therapy. Such information can 
greatly increase adherence to the regimen.
Patients are also advised about proper 
storage of all medication, for example, 
ritonavir should be kept in a fridge especially 
in our hot summer months.
Potential for drug interactions
The importance of considering the 
potential for drug interactions in patients 
receiving HAART cannot be overemphasized. 
Drug–drug interactions may involve 
positive or negative interactions between 
antiretroviral agents or between these 
and drugs used to treat other coexistent 
conditions.
Clinically important interactions to 
consider when co-administering with 
antiretroviral drugs include interactions with 
the following drugs: 
•	 methadone
•	 oral	contraceptives	
 (oestrogen-containing)
•	 anti-epileptics
•	 antidepressants
•	 lipid-lowering	agents
•	 acid-reducing	agents
•	 certain	antimicrobials	
 (e.g. clarithromycin, minocycline 
 and fluconazole)
•	 some	anti-arrhythmics
•	 tuberculosis	therapy
•	 anti-cancer	drugs
•	 immunosuppressant	
•	 phosphodiesterase	inhibitors
•	 anti-hepatitis	C	therapies
Many of these interactions are 
manageable (i.e. with/without dosage 
modifications, together with enhanced 
clinical vigilance) but in some cases 
(e.g. rifampicin and PIs) and didanosine 
and ribavirin (used in hepatitis C), the 
nature of the interaction is such that co-
administration must be avoided. 
The busy healthcare professional can turn 
to the local drug information pharmacists 
when seeking to check for potential drug 
interactions. In addition, the University of 
Liverpool’s comprehensive drug interaction 
website7 is an excellent and highly 
recommended resource. 
Conclusion
With the dramatic decrease in 
opportunistic infections brought about 
by the standard use of HAART, the care 
of patients infected with HIV has largely 
been transferred to the outpatient setting. 
Consequently, community pharmacists will be 
increasingly involved in the outpatient care 
of HIV-infected patients by ensuring patient 
adherence to complex treatment regimens 
and providing pharmaceutical care.
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